Newsbenzinga
Merck Reports Topline Results From Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart
· Published
Article summary
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an
An excerpt from the original article.
Comments —
Loading comments…